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INTRODUCTION
Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection and a major cause of hospitalizations in young children [1] . In preterm infants, the risk for severe RSV disease may lead to hospitalization and, in some cases, intensive care unit (ICU) admissions and mechanical ventilatory support [2] . Palivizumab (MedImmune, Gaithersburg, MD, USA) is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by RSV in high-risk children [3] . The American Academy of Pediatrics (AAP) first published guidance for use of palivizumab prophylaxis against RSV in 1998 and subsequently updated them in 2000, 2003, 2006, 2009, and 2012 [4] . These later iterations of the guidance narrowed the population recommended for prophylaxis with a focus on the increased risk and severity of RSV disease associated with younger gestational age and younger chronologic age [4, 5] . Using low estimates, the number of additional RSVH that would be associated with the 2014 guidance relative to the 2012 guidance was 958 for infants 29-31 wGA and 945 for infants 32-34 wGA (Fig. 3a) . Based on moderate estimates, the numbers of additional RSVH that would be associated with the 2014 guidance relative to the 2012 guidance were 1357 and 1229 for infants 29-31 and 32-34 wGA, respectively (Fig. 3b) . The high estimates for the number of additional RSVH that would be associated with the 2014 guidance relative to the 2012 guidance were 1916 for infants 29-31 wGA and 1891 for infants 32-34 wGA (Fig. 3c) . Fig. 1 Modeling the potential impact of the 2014 AAP guidance on RSV outcomes in preterm infants. AAP American Academy of Pediatrics, CDC Centers for Disease Control and Prevention, CLD chronic lung disease, ICU intensive care unit, RSV respiratory syncytial virus, wGA weeks' gestational age The data justifying the 2014 COID guidance on palivizumab use have been questioned, because they rely on reinterpretation of historical studies that were previously cited by AAP in support of palivizumab use, along with newer studies conducted in years in which palivizumab use was widespread [7, 11] . The 2014 AAP policy asserted, ''In recent large cohort studies of moderately preterm infants, the majority of whom did not receive palivizumab, 2.5% to 4.9% required hospitalization for RSV infection during the RSV season indicating that more than 95% did not require hospitalization [4] given that there is not routine testing for RSV, even among preterm infants [11] . Findings from the present study predict that the 2014 AAP guidance will result in additional burden to the healthcare system and families of preterm infants. 
CONCLUSION

